NBE-Therapeutics AG

NBE-Therapeutics AG is a biotechnology firm focused on developing advanced antibody-drug conjugates (ADCs) to treat solid tumors, employing innovative technologies for targeted cancer therapies. Founded in 2012 and headquartered in Basel, Switzerland, NBE-Therapeutics AG specializes in innovative oncology treatments. The company has completed a total of 12 deals, with its most recent being a TRADE SALE to Boehringer Ingelheim International GmbH for EUR 1180. 00 mn, finalized on December 10, 2020.

The CEO, Jean Engela, has been pivotal in leading the company since its inception. NBE Therapeutics specializes in the development of next-generation antibody-drug conjugates (ADCs) aimed at treating solid tumors in oncology. Their core offerings revolve around a proprietary platform that integrates novel technologies to create targeted therapies designed to enhance the efficacy of cancer treatment while minimizing side effects. The company’s ADCs leverage long-lasting immune oncology effects which could potentially reduce or eradicate tumors, thereby improving survival rates and quality of life for cancer patients.

These innovative products are primarily aimed at healthcare institutions, oncologists, and research organizations across North America and Europe, where they serve an extensive client base committed to advancing cancer care. NBE Therapeutics maintains a robust pipeline of product candidates at various development stages, all aimed at addressing the urgent need for more selective and effective cancer therapies. NBE Therapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers. The company’s revenue structure includes B2B transactions where they supply their ADC product candidates to partners engaged in clinical trials and subsequent commercialization efforts.

Each partnership may involve milestone payments and royalties based on the sales performance of developed therapies. Through these collaborations, NBE Therapeutics aims to accelerate the development and market availability of its flagship products, which are designed to target specific cancer types with precision and effectiveness. With the recent acquisition by Boehringer Ingelheim International GmbH, NBE-Therapeutics AG is positioned for significant growth. The company plans to utilize the EUR 1180.

00 mn from the latest TRADE SALE to expand its product pipeline and enter new markets. Specific targets for future product launches are expected in the upcoming years, focusing on enhancing ADC therapies and expanding into Asian markets, particularly in Japan and China, by 2023.